AR076184A1 - Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo. - Google Patents

Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.

Info

Publication number
AR076184A1
AR076184A1 ARP100101113A ARP100101113A AR076184A1 AR 076184 A1 AR076184 A1 AR 076184A1 AR P100101113 A ARP100101113 A AR P100101113A AR P100101113 A ARP100101113 A AR P100101113A AR 076184 A1 AR076184 A1 AR 076184A1
Authority
AR
Argentina
Prior art keywords
cis
formulation
lipid vehicle
lipid
pharmaceutical formulations
Prior art date
Application number
ARP100101113A
Other languages
English (en)
Inventor
Ronald Erwin Boch
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of AR076184A1 publication Critical patent/AR076184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

Formulaciones farmacéuticas que comprenden 9-cis-retinil ésteres en un vehiculo lipídico como terapias de reemplazo de retinoides para el tratamiento de degeneraciones de la retina en humanos. Reivindicacion 1: Una formulacion farmacéutica caracterizada porque comprende un vehículo lipídico y uno o más 9-cis-retinil ésteres de formula (1) donde R es un grupo alquilo o un grupo alquenilo y donde el vehículo lipídico comprende más de 50% p/p de ácidos grasos poliinsaturados donde los ácidos grasos poliinsaturados incluyen un ácido graso omega-6 y un ácido graso omega-3 en una proporcion (en peso) menor que 15. Reivindicacion 5: La formulacion farmacéutica de cualquiera de las reivindicaciones 1-4, caracterizada porque el vehículo lipídico comprende un linoleato de un triglicérido y un linolenato de un triglicérido en una proporcion (en peso) menor que 15, los cuales colectivamente constituyen más de 50% del peso total del vehículo lipídico. Reivindicacion 15: La formulacion de cualquiera de las reivindicaciones 1-14, caracterizada porque la formulacion es una bebida que comprende acetato de 9-cis-retinilo, aceite de soja y una emulsion. Reivindicacion 16: La formulacion de la reivindicacion 15, caracterizada porque la emulsion es leche de soja, leche o una mezcla de éstas.
ARP100101113A 2009-09-15 2010-03-31 Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo. AR076184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24274109P 2009-09-15 2009-09-15
PCT/US2009/059126 WO2011034551A2 (en) 2009-09-15 2009-09-30 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle

Publications (1)

Publication Number Publication Date
AR076184A1 true AR076184A1 (es) 2011-05-26

Family

ID=43242391

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101113A AR076184A1 (es) 2009-09-15 2010-03-31 Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.

Country Status (13)

Country Link
US (3) US20120178806A1 (es)
JP (2) JP5663025B2 (es)
KR (1) KR101710505B1 (es)
CN (1) CN102612375B (es)
AR (1) AR076184A1 (es)
AU (1) AU2009352678B2 (es)
CA (1) CA2774168C (es)
HK (1) HK1170158A1 (es)
IN (1) IN2012DN02466A (es)
MX (1) MX2012003220A (es)
MY (1) MY174082A (es)
RU (1) RU2546005C2 (es)
WO (1) WO2011034551A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009352678B2 (en) 2009-09-15 2015-05-21 Eluminex Biosciences (Suzhou) Limited Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
EP2563350B1 (en) * 2010-04-19 2020-10-14 Retinagenix Therapeutics, Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2718261B1 (en) * 2011-06-08 2016-02-24 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity
BR112014021602A2 (pt) 2012-03-01 2021-06-08 Quadra Logic Tech Inc uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide
US12029715B2 (en) 2015-05-08 2024-07-09 University Of Debrecen Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
WO2018091937A1 (en) 2016-11-17 2018-05-24 University Of Debrecen Precursor compounds for providing retinoids of the vitamin a5 pathway and uses thereof
US11019830B2 (en) * 2015-06-30 2021-06-01 Conopco Inc. Composition containing vegetable oil, caramel and phenolic compounds
IL262583B2 (en) * 2016-04-28 2023-10-01 Spark Therapeutics Inc Relative potency assay for a vector encoding isomerohydrolases
MX2022015602A (es) * 2020-06-09 2023-03-03 Eluminex Biosciences Suzhou Ltd Metodos de tratamiento de trastornos visuales utilizando una dosificacion baja diaria de un compuesto retinoide.

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (es) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) * 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
US4532133A (en) * 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
EP0839029A1 (en) * 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US5744148A (en) * 1996-09-20 1998-04-28 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20020142016A1 (en) * 2000-12-28 2002-10-03 Granger Stewart Paton Stable skin care product containing a retinoid and a retinoid booster system in a dual compartment package
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
AU2002333114B2 (en) * 2001-11-30 2008-09-04 Qlt Inc. Hydrazonopyrazole derivatives and their use as therapeutics
WO2003059336A1 (en) 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003082081A2 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
JP3854524B2 (ja) 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP2327400A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
EP1510133A1 (en) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
JP4979381B2 (ja) 2003-09-04 2012-07-18 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 暗順応障害を検出するための方法及び装置
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
EP1722766A2 (en) 2004-02-17 2006-11-22 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
SI1765322T1 (sl) 2004-06-18 2014-03-31 University Of Washington Intellectual Property And Technology Transfer 4311 Derivati retinala in postopki za njihovo uporabo za zdravljenje motenj vida
DK1768657T3 (da) 2004-06-23 2008-12-01 Sirion Therapeutics Inc Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
US20060240098A1 (en) * 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
JP2008515778A (ja) 2004-08-18 2008-05-15 シリオン セラピューティクス， インコーポレイテッド 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
US20080275133A1 (en) 2004-09-30 2008-11-06 University Of Calfornia-San Francisco Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
JP2009514890A (ja) * 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
US8202541B2 (en) * 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2972344C (en) 2007-01-15 2021-10-26 Chongxi Yu Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
US8877809B2 (en) 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
AU2009352678B2 (en) 2009-09-15 2015-05-21 Eluminex Biosciences (Suzhou) Limited Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
EP2563350B1 (en) 2010-04-19 2020-10-14 Retinagenix Therapeutics, Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency

Also Published As

Publication number Publication date
KR101710505B1 (ko) 2017-02-27
AU2009352678B2 (en) 2015-05-21
US20120178806A1 (en) 2012-07-12
RU2546005C2 (ru) 2015-04-10
CA2774168A1 (en) 2011-03-24
CN102612375B (zh) 2016-01-27
AU2009352678A1 (en) 2012-04-05
US20190183835A1 (en) 2019-06-20
WO2011034551A2 (en) 2011-03-24
JP5663025B2 (ja) 2015-02-04
JP2014185185A (ja) 2014-10-02
US20170007565A1 (en) 2017-01-12
IN2012DN02466A (es) 2015-08-21
US10736865B2 (en) 2020-08-11
RU2012114791A (ru) 2013-10-27
US10130606B2 (en) 2018-11-20
WO2011034551A3 (en) 2011-12-15
CN102612375A (zh) 2012-07-25
HK1170158A1 (zh) 2013-02-22
CA2774168C (en) 2021-02-23
JP2013504617A (ja) 2013-02-07
BR112012005905A2 (pt) 2020-02-18
MY174082A (en) 2020-03-09
MX2012003220A (es) 2012-08-03
KR20120064707A (ko) 2012-06-19

Similar Documents

Publication Publication Date Title
AR076184A1 (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.
MX356427B (es) Emulsion que contiene hormona.
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
CO6501136A2 (es) Composiciones que comprenden una mezcla de aceite de ácido graso y un tensoactivo, y métodos y usos de las mismas
PE20170253A1 (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
AR101192A1 (es) Composición nutricional que contiene mezclas de aceites y método de promoción de la digestión de grasas y lípidos
GEP201606568B (en) Compositions for the treatment of neurologic disorders
BR112014013593A8 (pt) retenção de dha durante o processamento de óleo de canola
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
BR112015020671A2 (pt) método de aumentar a biodisponibilidade da dha e outros nutrientes solúveis em lipídeos
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
MX2020002238A (es) Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias.
HRP20201221T1 (hr) Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
AR094529A1 (es) Composición nutricional sustituta de la crema
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
CO6390033A2 (es) Ácido graso pliinsaturado y éster de diol como agente anti-acné
MX2012001718A (es) Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente.
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
CL2017002828A1 (es) Composición para tratamiento de estrés oxidativo y enfermedad cardiovascular
CO2018009407A2 (es) Composición y método para el tratamiento del deterioro cognitivo

Legal Events

Date Code Title Description
FC Refusal